CSIMarket Company Name, Ticker, Industry, else..
 
Ayala Pharmaceuticals Inc   (ADXS)
 
Price: $0.6036 $0.05 8.757%
Day's High: $0.6195 Week Perf: 18.01 %
Day's Low: $ 0.60 30 Day Perf: 1083.53 %
Volume (M): 13,500 52 Wk High: $ 0.70
Volume (M$): $ 8 52 Wk Avg: $0.16
Open: $0.62 52 Wk Low: $0.00



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 6
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -48
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Ayala Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that focuses on developing targeted cancer therapies. The company's goal is to improve the outcomes for patients with rare and aggressive cancers by leveraging precision medicine and advanced genomic profiling. Ayala Pharmaceuticals specializes in developing small molecule drugs that target specific genetic alterations found in cancer cells. Their lead product candidate, AL101, is being evaluated in clinical trials for the treatment of patients with advanced solid tumors and recurrent/metastatic adenoid cystic carcinoma (ACC). The company is committed to advancing its pipeline and bringing promising therapies to market, ultimately providing better treatment options for cancer patients.


   Company Address: 9 Deer Park Drive Monmouth Junction 8852 NJ
   Company Phone Number: 452-9813   Stock Exchange / Ticker: ADXS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.11%    
JNJ        1.82% 
LLY        2.69% 
MRK        3.55% 
OGN        0.26% 
REGN        4.17% 
• View Complete Report
   



Product Service News

Completing Patient Enrollments: A Milestone for Ayala Pharmaceuticals' Promising Desmoid Tumor Study

Published Tue, Feb 20 2024 1:15 PM UTC

Immunome Recognizes Completion of Patient Enrollment in Ayala Pharmaceuticals Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsBOTHELL, Wash. - Immunome, Inc. recently acknowledged the announcement made by Ayala Pharmaceuticals, Inc. regarding the completion of patient enrollment in the Phase 3 RINGSIDE study. The study aims to evaluate the efficacy of AL102, a targ...
Product Service News

Immunome Acquires AL102 and AL101, Groundbreaking Drug Candidates for the Treatment of Desmoid Tumors, from Ayala Pharmaceuticals.

Published Tue, Feb 6 2024 1:00 PM UTC

Immunome Acquires AL102, a Promising Phase 3 Asset for the Treatment of Desmoid Tumors, from Ayala PharmaceuticalsIn a significant development in the field of targeted cancer therapies, Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on groundbreaking cancer treatments, has announced its acquisition of AL102 and the related drug candidate AL101 from Ayala Phar...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 279.47
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.2
Working Capital Ratio 0.3
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -9.12 $
Revenues (TTM) 0 $
Cash Flow (TTM) 0.41 $
Cash 0.81 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -4,370,182
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.